Dopamine is an inhibitory neurotransmitter involved in the pathology of schizophrenia. The
revised dopamine hypothesis states that dopamine abnormalities in the mesolimbic and …

Many sex and gender differences in schizophrenic psychoses have been reported, but few
have been soundly replicated. A stable finding is the later age of onset in women compared …

This guidance paper from the European Psychiatric Association (EPA) aims to provide
evidence-based recommendations on early intervention in clinical high risk (CHR) states of …

The thalamus is a crucial node for brain physiology and part of functional and structural
pathways relevant for schizophrenia. Relatively few imaging studies on schizophrenia have …

Individuals at clinical high-risk (CHR) for psychosis are characterized by attenuated
psychotic symptoms. Only a minority of CHR individuals convert to full-blown psychosis …

To date, the MRI-based individualized prediction of psychosis has only been demonstrated
in single-site studies. It remains unclear if MRI biomarkers generalize across different …

Characterizing neuroanatomical markers of different stages of schizophrenia (SZ) to assess
pathophysiological models of how the disorder develops is an important target for the …

One of the few well-replicated features of schizophrenia is the demonstration of
neuroanatomical abnormalities affecting cortical and subcortical grey matter (GM). Evidence …

The location, extent and progression of longitudinal morphometric changes after first-
episode of psychosis (FEP) remains unclear. We investigated ventricular and cortico …

Brain changes in schizophrenia evolve along a dynamic trajectory, emerging before disease
onset and proceeding with ongoing illness. Recent investigations have focused attention on …